Results 191 to 200 of about 98,145 (299)

Emergency Department Opt‐Out Testing for Hepatitis B: A Two‐Year UK Multicentre Evaluation of Outcomes Across Seven Sites

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aims An estimated 270 000 people in the UK live with hepatitis B infection, the leading global cause of liver cancer. In 2022, opt‐out hepatitis B testing was introduced in emergency departments (ED) in London. We conducted a 2‐year multicentre evaluation of this programme across seven sites.
Jennifer J. Plunkett, Basil Ahmad, Amy Teague, Tanzina Haque, Stephanie Paget, Jennifer Hart, Maximillian Habibi, Jonathan Durban, Shiny Jaimes, Sally Thomas, Helen Boothman, Supa Chantschool, Philippa C. Matthews, Rachel Hill‐Tout, Daniel Forton, Douglas Macdonald   +15 more
wiley   +1 more source

Trends in the seroprevalence of hepatitis C viruses among patients received at the Centre Pasteur du Cameroun, with an indication of anti-HCV Ac serology from 2019 to 2024. [PDF]

BMC Infect Dis
Mounchili-Njifon A, Mbouyap PR, Ngono L, Nsai EB, Epote A, Belinga S, Njouom R.   +6 more
europepmc   +1 more source

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. [PDF]

J Antimicrob Chemother, 2021
Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias SDSG, da Silva CDS, Ferreira AC, Mattos M, Pão CRR, de Freitas CS, Soares VC, Hoelz LVB, Fernandes TVA, Branco FSC, Bastos MM, Boechat N, Saraiva FB, Ferreira MA, Jockusch S, Wang X, Tao C, Chien M, Xie W, Patel D, Garzia A, Tuschl T, Russo JJ, Rajoli RKR, Pedrosa CSG, Vitória G, Souza LRQ, Goto-Silva L, Guimarães MZ, Rehen SK, Owen A, Bozza FA, Bou-Habib DC, Ju J, Bozza PT, Souza TML.   +39 more
europepmc   +1 more source

Real‐World Outcomes of Opti‐Hep‐D: An Innovative, Multicentre and Multidisciplinary Program Improving Hepatitis D Cascade of Care

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aim Hepatitis D virus (HDV) infection remains underdiagnosed, and real‐world data on screening and linkage to care are limited. We assessed the implementation of Opti‐Hep‐D, a publicly funded initiative for HDV management in the Spanish region of Catalonia.
Adriana Palom, Ariadna Rando‐Segura, Laura Calatayud‐Samper, Gema Fernández‐Rivas, Alicia Sellés‐Sanchez, Saray Mormeneo‐Bayo, Dúnia Pérez del Campo, Eva del Corral, Tomàs Balari, Rosa Maria Morillas, Adrià Rodríguez‐Castellano, Patricia Huelin, Carmen Lopez, Darly Salazar, Joana Villaverde, Indiana Abdo, José Castellote, Joan Carles Quer Boniquet, Carles Aracil Blanch, Andrés Marco, Maria Buti   +20 more
wiley   +1 more source

Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment. [PDF]

PLoS One
Kanokudom S, Poovorawan K, Nilyanimit P, Suntronwong N, Aeemjinda R, Honsawek S, Poovorawan Y.   +6 more
europepmc   +1 more source

The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. [PDF]

Mol Divers, 2022
Elfiky AA, Azzam EB, Shafaa MW.
europepmc   +1 more source

Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aims To evaluate the prognostic significance of pathological response in patients with initially unresectable hepatocellular carcinoma (uHCC) who underwent salvage resection after successful conversion with lenvatinib, anti‐PD‐1 antibodies, and locoregional therapy (LPLRT).
Qi‐Yu Chi, Xiao‐Di Gao, Mi Wang, Quan‐Yuan Liu, Yong‐Yi Zeng, Lan‐Fang Yang, Zi‐Jian Liu, Shuang‐Jia Wang, Shan‐Geng Weng, Zhi‐Bo Zhang   +9 more
wiley   +1 more source

Prevalence-based screening by anti-HCV reflex HCV antigen test and accessible post-screening care towards elimination of hepatitis C in rural villages. [PDF]

BMC Gastroenterol
Pan KC, Hsu NT, Tang YM, Lee YC, Kuo HL, Huang TJ, Tseng CM, Lu SN, Chang TS.   +8 more
europepmc   +1 more source

Janus Dendrimers to Assess the Anti-HCV Activity of Molecules in Cell-Assays. [PDF]

Pharmaceutics, 2020
San Anselmo M, Lancelot A, Egido JE, Clavería-Gimeno R, Casanova Á, Serrano JL, Hernández-Ainsa S, Abian O, Sierra T.   +8 more
europepmc   +1 more source

Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Evidence supporting the safety and efficacy of immune checkpoint inhibitors (ICI) before liver transplantation (LTx) in hepatocellular carcinoma (HCC) is increasing, but risks of graft rejection and tumour recurrence remain major concerns. We evaluated post‐transplant outcomes across 10 European centres using data from the multinational LITCHI
Ulrike Bauer, Maria R. Troppmair, Najib Ben Khaled, Julia M. Grottenthaler, Friedrich Foerster, Sena Blümel, Sophia Heinrich, Friedrich Sinner, Matthias Pinter, Magdalena Hahn, Florian van Bömmel, Bernhard Scheiner, Marino Venerito, Richard Taubert, Andreas E. Kremer, Arndt Weinmann, Christoph P. Berg, Christian M. Lange, Enrico N. De Toni, Angela Djanani, Heinz Zoller, Roland M. Schmid, Ursula Ehmer   +22 more
wiley   +1 more source